BI Asset Management Fondsmaeglerselskab A S Decreases Position in Bristol Myers Squibb Company $BMY

BI Asset Management Fondsmaeglerselskab A S decreased its stake in Bristol Myers Squibb Company (NYSE:BMY) by 69.7% in the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 81,098 shares of the biopharmaceutical company’s stock after selling 186,555 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in Bristol Myers Squibb were worth $4,946,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in BMY. Legacy Financial Advisors Inc. boosted its holdings in shares of Bristol Myers Squibb by 6.5% in the first quarter. Legacy Financial Advisors Inc. now owns 13,381 shares of the biopharmaceutical company’s stock valued at $816,000 after purchasing an additional 813 shares during the period. bLong Financial LLC raised its holdings in shares of Bristol Myers Squibb by 3.7% in the first quarter. bLong Financial LLC now owns 13,963 shares of the biopharmaceutical company’s stock valued at $852,000 after acquiring an additional 500 shares in the last quarter. CWS Financial Advisors LLC purchased a new stake in Bristol Myers Squibb in the first quarter worth about $205,000. Wellington Management Group LLP grew its holdings in Bristol Myers Squibb by 297.0% during the 1st quarter. Wellington Management Group LLP now owns 23,728,443 shares of the biopharmaceutical company’s stock worth $1,447,198,000 after acquiring an additional 17,750,938 shares in the last quarter. Finally, Cornerstone Select Advisors LLC increased its position in Bristol Myers Squibb by 2.0% during the 1st quarter. Cornerstone Select Advisors LLC now owns 29,178 shares of the biopharmaceutical company’s stock valued at $1,780,000 after purchasing an additional 568 shares during the period. 76.41% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on BMY. Daiwa Capital Markets downgraded shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price objective on the stock. in a research note on Tuesday, August 5th. Wall Street Zen cut Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 6th. Argus raised Bristol Myers Squibb to a “hold” rating in a research report on Friday, April 25th. Daiwa America cut Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 5th. Finally, Jefferies Financial Group cut their target price on Bristol Myers Squibb from $70.00 to $68.00 and set a “buy” rating on the stock in a research note on Wednesday, April 23rd. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $56.38.

Bristol Myers Squibb Stock Down 0.2%

Shares of BMY stock opened at $48.2470 on Thursday. The stock’s fifty day moving average price is $47.14 and its 200 day moving average price is $51.28. Bristol Myers Squibb Company has a 1-year low of $42.96 and a 1-year high of $63.33. The company has a market cap of $98.20 billion, a price-to-earnings ratio of 19.45, a price-to-earnings-growth ratio of 2.47 and a beta of 0.36. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.07 by $0.39. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The business had revenue of $12.27 billion during the quarter, compared to the consensus estimate of $11.32 billion. During the same quarter last year, the company earned $2.07 earnings per share. The company’s quarterly revenue was up .6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. On average, research analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd were issued a $0.62 dividend. The ex-dividend date of this dividend was Thursday, July 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.1%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 100.00%.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.